Telomerase-dependent oncolytic adenovirus sensitizes human cancer cells to ionizing radiation via inhibition of DNA repair machinery

Cancer Research

Volumn 70, Issue 22, 2010, Pages 9339-9348

  Kuroda, Shinji ^a   Fujiwara, Toshiya ^a   Shirakawa, Yasuhiro ^a   Yamasaki, Yasumoto ^a   Yano, Shuya ^a   Uno, Futoshi ^a   Tazawa, Hiroshi ^b   Hashimoto, Yuuri ^a   Watanabe, Yuichi ^a,c   Noma, Kazuhiro ^a   Urata, Yasuo ^c   Kagawa, Shunsuke ^a   Fujiwara, Toshiyoshi ^a,b  

^a OKAYAMA UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^c National Institute of Infectious Diseases   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MRE11 PROTEIN; NIBRIN; OBP 301; ONCOLYTIC ADENOVIRUS; RAD50 PROTEIN; TELOMELYSIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ATAXIA TELANGIECTASIA; CANCER CELL; CONTROLLED STUDY; DNA REPAIR; DOUBLE STRANDED DNA BREAK; ESOPHAGUS CANCER; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; IONIZING RADIATION; IRRADIATION; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SENSITIZATION; SIGNAL TRANSDUCTION; WHOLE BODY IMAGING;

ADENOVIRIDAE; ADENOVIRUS E1B PROTEINS; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; COMBINED MODALITY THERAPY; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; ESOPHAGEAL NEOPLASMS; FEMALE; FLOW CYTOMETRY; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS; NUCLEAR PROTEINS; ONCOLYTIC VIROTHERAPY; RADIATION, IONIZING; TELOMERASE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78549274429     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-2333     Document Type: Article

References (40)

1. Bentzen SM, Harari PM, Bernier J. Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions. Nat Clin Pract Oncol 2007;4:172-80.
2. Bradley KA, Pollack IF, Reid JM, et al. Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a Children's Oncology Group phase I study. Neuro Oncol 2008;10:752-8.
3. Hoskin P, Rojas A, Saunders M. Accelerated radiotherapy, carbogen, and nicotinamide (ARCON) in the treatment of advanced bladder cancer: mature results of a Phase II nonrandomized study. Int J Radiat Oncol Biol Phys 2009;73:1425-31.
4. Kim CH, Park SJ, Lee SH. A targeted inhibition of DNA-dependent protein kinase sensitizes breast cancer cells following ionizing radiation. J Pharmacol Exp Ther 2002;303:753-9.
5. Tang X, Hui ZG, Cui XL, Garg R, Kastan MB, Xu B. A novel ATM-dependent pathway regulates protein phosphatase 1 in response to DNA damage. Mol Cell Biol 2008;28:2559-66.
6. Shiloh Y. Ataxia-telangiectasia and the Nijmegen breakage syndrome: related disorders but genes apart. Annu Rev Genet 1997;31:635-62.
7. Petrini JH. The Mre11 complex and ATM: collaborating to navigate S phase. Curr Opin Cell Biol 2000;12:293-6.
8. Sturgeon CM, Roberge M. G2 checkpoint kinase inhibitors exert their radiosensitizing effects prior to the G2/M transition. Cell Cycle 2007;6:572-5.
9. D'Amours D, Jackson SP. The Mre11 complex: at the crossroads of DNA repair and checkpoint signalling. Nat Rev Mol Cell Biol 2002;3:317-27.
10. Carson CT, Schwartz RA, Stracker TH, Lilley CE, Lee DV, Weitzman MD. The Mre11 complex is required for ATM activation and the G2/M checkpoint. EMBO J 2003;22:6610-20.
11. Theunissen JW, Kaplan MI, Hunt PA, et al. Checkpoint failure and chromosomal instability without lymphomagenesis in Mre11 (ATLD1/ATLD1) mice. Mol Cell 2003;12:1511-23.
12. Kawashima T, Kagawa S, Kobayashi N, et al. Telomerase-specific replication-selective virotherapy for human cancer. Clin Cancer Res 2004;10:285-92.
13. Umeoka T, Kawashima T, Kagawa S, et al. Visualization of intrathoracically disseminated solid tumors in mice with optical imaging by telomerase-specific amplification of a transferred green fluorescent protein gene. Cancer Res 2004;64:6259-65.
14. Taki M, Kagawa S, Nishizaki M, et al. Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 ('Telomelysin-RGD'). Oncogene 2005;24:3130-40.
15. Hashimoto Y, Watanabe Y, Shirakiya Y, et al. Establishment of biological and pharmacokinetic assays of telomerase-specific replication-selective adenovirus. Cancer Sci 2008;99:385-90.
16. Querido E, Marcellus RC, Lai A, et al. Regulation of p53 levels by the E1B 55-kilodalton protein and E4orf6 in adenovirus-infected cells. J Virol 1997;71:3788-98.
17. Stracker TH, Carson CT, Weitzman MD. Adenovirus oncoproteins inactivate the Mre11-50-NBS1 DNA repair complex. Nature 2002;418:348-52.
18. Schwartz RA, Lakdawala SS, Eshleman HD, Russell MR, Carson CT, Weitzman MD. Distinct requirements of adenovirus E1b55K protein for degradation of cellular substrates. J Virol 2008;82:9043-55.
19. Bischoff JR, Kirn DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996;274:373-6.
20. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006;58:621-81.
21. Crescenzi E, Palumbo G, de BJ, Brady HJ. Ataxia telangiectasia mutated and p21CIP1 modulate cell survival of drug-induced senescent tumor cells: implications for chemotherapy. Clin Cancer Res 2008;14:1877-87.
22. Cheng WH, Muftic D, Muftuoglu M, et al. WRN is required for ATM activation and the S-phase checkpoint in response to interstrand cross-link-induced DNA double-strand breaks. Mol Biol Cell 2008;19:3923-33.
23. Dupre A, Boyer-Chatenet L, Sattler RM, et al. A forward chemical genetic screen reveals an inhibitor of the Mre11-50-Nbs1 complex. Nat Chem Biol 2008;4:119-25.
24. Dote H, Burgan WE, Camphausen K, Tofilon PJ. Inhibition of hsp90 compromises the DNA damage response to radiation. Cancer Res 2006;66:9211-20.
25. Abuzeid WM, Jiang X, Shi G, et al. Molecular disruption of RAD50 sensitizes human tumor cells to cisplatin-based chemotherapy. J Clin Invest 2009;119:1974-85.
26. Blackford AN, Grand RJ. Adenovirus E1B 55-kilodalton protein: multiple roles in viral infection and cell transformation. J Virol 2009;83:4000-12.
27. Hart LS, Yannone SM, Naczki C, et al. The adenovirus E4orf6 protein inhibits DNA double strand break repair and radiosensitizes human tumor cells in an E1B-55K-independent manner. J Biol Chem 2005;280:1474-81.
28. Redon C, Pilch D, Rogakou E, Sedelnikova O, Newrock K, Bonner W. Histone H2A variants H2AX and H2AZ. Curr Opin Genet Dev 2002;12:162-9.
29. Banath JP, Macphail SH, Olive PL. Radiation sensitivity, H2AX phosphorylation, and kinetics of repair of DNA strand breaks in irradiated cervical cancer cell lines. Cancer Res 2004;64:7144-9.
30. Endo Y, Sakai R, Ouchi M, et al. Virus-mediated oncolysis induces danger signal and stimulates cytotoxic T-lymphocyte activity via proteasome activator upregulation. Oncogene 2008;27:2375-81.
31. Ewald B, Sampath D, Plunkett W. H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation. Mol Cancer Ther 2007;6:1239-48.
32. Cook PJ, Ju BG, Telese F, Wang X, Glass CK, Rosenfeld MG. Tyrosine dephosphorylation of H2AX modulates apoptosis and survival decisions. Nature 2009;458:591-6.
33. Fidler IJ. Rationale and methods for the use of nude mice to study the biology and therapy of human cancer metastasis. Cancer Metastasis Rev 1986;5:29-49.
34. Tsai JH, Makonnen S, Feldman M, Sehgal CM, Maity A, Lee WM. Ionizing radiation inhibits tumor neovascularization by inducing ineffective angiogenesis. Cancer Biol Ther 2005;4:1395-400.
35. Abdollahi A, Lipson KE, Sckell A, et al. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. Cancer Res 2003;63:8890-8.
36. Ikeda Y, Kojima T, Kuroda S, et al. A novel antiangiogenic effect for telomerase-specific virotherapy through host immune system. J Immunol 2009;182:1763-9.
37. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001;93:266-76.
38. Nishi H, Nakada T, Kyo S, Inoue M, Shay JW, Isaka K. Hypoxia-inducible factor 1 mediates upregulation of telomerase (hTERT). Mol Cell Biol 2004;24:6076-83.
39. Kishimoto H, Kojima T, Watanabe Y, et al. In vivo imaging of lymph node metastasis with telomerase-specific replication-selective adenovirus. Nat Med 2006;12:1213-9.
40. Kurihara Y, Watanabe Y, Onimatsu H, et al. Telomerase-specific virotheranostics for human head and neck cancer. Clin Cancer Res 2009;15:2335-43.